Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Restructuring Costs (2023 - 2025)

Historic Restructuring Costs for Sunshine Biopharma (SBFM) over the last 5 years, with Q3 2025 value amounting to $614661.0.

  • Sunshine Biopharma's Restructuring Costs rose 1590.07% to $614661.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 1315.14%. This contributed to the annual value of $3.1 million for FY2024, which is 4516.86% up from last year.
  • Per Sunshine Biopharma's latest filing, its Restructuring Costs stood at $614661.0 for Q3 2025, which was up 1590.07% from $806605.0 recorded in Q2 2025.
  • Sunshine Biopharma's 5-year Restructuring Costs high stood at $925878.0 for Q1 2025, and its period low was $530334.0 during Q3 2024.
  • For the 3-year period, Sunshine Biopharma's Restructuring Costs averaged around $741389.1, with its median value being $720297.0 (2023).
  • Data for Sunshine Biopharma's Restructuring Costs shows a peak YoY increase of 2578.92% (in 2024) and a maximum YoY decrease of 255.06% (in 2024) over the last 5 years.
  • Quarter analysis of 3 years shows Sunshine Biopharma's Restructuring Costs stood at $720297.0 in 2023, then rose by 25.79% to $906056.0 in 2024, then tumbled by 32.16% to $614661.0 in 2025.
  • Its Restructuring Costs was $614661.0 in Q3 2025, compared to $806605.0 in Q2 2025 and $925878.0 in Q1 2025.